PTAB Upholds DNA Testing Patents Key To $272M Ravgen Win
The Patent Trial and Appeal Board has rejected biotechnology company Streck's contention that nearly 30 claims in a Ravgen genetic testing patent are obvious or anticipated, siding with the patent owner...To view the full article, register now.
Already a subscriber? Click here to view full article